meta|evidence oncology

Living systematic review and meta-analysis

endometrial cancer - (neo)adjuvant (NA) 1
esophageal cancer (EC)

immune chekpoint inhibitors
anti-PD-(L)1
camrelizumab based treatment
camrelizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC

versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -